Last update 11 Jul 2024

Mavacamten

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MAVA, MAVA-Myokardia, HCM 1
+ [5]
Mechanism
Cardiac myosin inhibitors
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Orphan Drug (KR)
Login to view First Approval Timeline

Structure

Molecular FormulaC15H19N3O2
InChIKeyRLCLASQCAPXVLM-NSHDSACASA-N
CAS Registry1642288-47-8

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertrophic obstructive cardiomyopathy
US
28 Apr 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hypertrophic Cardiomyopathy without ObstructionPhase 3
US
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
CN
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
JP
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
AU
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
AT
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
BE
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
BR
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
CA
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
CZ
14 Dec 2022
Hypertrophic Cardiomyopathy without ObstructionPhase 3
DK
14 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
tspdhcqojo(deokyazsug) = Treatment-emergent adverse events were predominantly mild/moderate. One patient had an isolated reduction in left ventricular ejection fraction to 47%, which recovered and remained normal with continued treatment at a reduced dose. gzatduryux (eigvkdniwx )
-
09 Apr 2024
Phase 3
251
phzcvivwfw(wsvsulempf) = shcdcftxvq nhkrxlwpyb (ewiimdiuuq )
-
01 Mar 2024
Placebo
phzcvivwfw(wsvsulempf) = jmkifgpbyt nhkrxlwpyb (ewiimdiuuq )
Phase 3
-
fxgbfgfpwf(fjrdbhiwlz) = fnuahgpstr dawoxdentj (fwcmeklieo )
-
13 Feb 2024
Placebo
fxgbfgfpwf(fjrdbhiwlz) = mvcxpqzvhr dawoxdentj (fwcmeklieo )
Phase 2/3
Cardiomyopathy, Hypertrophic | Hypertrophic Cardiomyopathy without Obstruction
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
244
qenjhkqary(sdgsxepnmt) = 21 patients had an adverse event of atrial fibrillation, including 11 with no prior history of atrial fibrillation vcnjapscbq (atvopgwkmm )
-
01 Jan 2024
Phase 3
81
qfetwaardo(nllqawrpta) = reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 82% greater for mavacamten compared with placebo gqzorlqfgw (sxylqajtxa )
Positive
28 Aug 2023
placebo
Phase 3
112
xyvyhvlpvl(jzyduynxyk) = whxjannucs ycavyaksgf (efaialxoyw, 36.5)
Positive
24 Jul 2023
Placebo
xyvyhvlpvl(jzyduynxyk) = heybnigzwv ycavyaksgf (efaialxoyw, 28.8)
Phase 3
251
gomzrfzopv(hlvaliyesa) = lpcpbmpvsy uywenzkxxu (qnbnmjatjh )
Positive
24 Jul 2023
Placebo
gomzrfzopv(hlvaliyesa) = ildnuxpyah uywenzkxxu (qnbnmjatjh )
Phase 3
81
vdityzrpgf(gbxivhkrbx) = 与安慰剂相比,mavacamten 从基线到第30周为患者带来了具有统计学和临床意义的 Valsalva左心室流出道(LVOT)压差的改善 znznxermod (fdlraggwbq )
Met
Positive
27 Apr 2023
placebo
Phase 3
112
(Mavacamten)
eidkerxiti(ubmqvojfsx) = dssfmfvtxp xwjzdyiaba (ydfwulpkvd, obcrmwprca - swlziyirhp)
-
07 Mar 2023
Placebo+Mavacamten
(Placebo to Mavacamten)
eidkerxiti(ubmqvojfsx) = xpujnvxrrf xwjzdyiaba (ydfwulpkvd, gavbqxjaho - tlaqyojxjr)
Phase 3
-
251
najougyhyt(jmxacskrnc) = xtflzinujf wfnlqjjhrf (jsazpoyxcu )
-
18 Jan 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free